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Early in April 2009, several patients infected 
with novel H1N1 swine-origin influenza virus A
(S-OIV A) were found in the United States and
Mexico. Through rapid and frequent international
travel, it has spread to over 74 countries around
the world and over 29,000 cases, including 145
deaths, have been reported up to June 12, 2009.1
On June 11, 2009, the World Health Organization
declared an influenza pandemic, caused by novel
S-OIV A (H1N1).
The three previous influenza pandemics,
A/H1N1 from 1918 to 1919, A/H2N2 from 1957
to 1963, and A/H3N2 from 1968 to 1970, were
characterized by a shift in the virus subtype, a shift
in the highest mortality to younger populations,
successive pandemic waves, higher transmissibility
than seasonal influenza, and different impacts in
different geographic regions.2 The present novel
H1N1 influenza has one of the most important
characteristics, a shift in virus subtype, and it is very
possible the other characteristics will develop.
Clinical Manifestations
According to a report of 642 confirmed cases of
novel S-OIV A (H1N1) infection in the United
States, patients ranged from 3 months to 81 years
in age; 60% of patients were ≤ 18 years, 40% were
10–18 years, and only 5% were ≥ 51 years.3 There-
fore, younger populations were much more 
susceptible than the elderly. The most common
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An influenza epidemic was detected in April 2009 at the border between the United States and Mexico.
The virus was identified soon after to be a swine-origin influenza virus A (S-OIV A) (H1N1). This virus has
an HA gene that is derived from the 1918 swine influenza virus and other genes from human, avian, and
Eurasian swine influenza viruses. Clinically, it behaves similarly to seasonal influenza. The only differen-
tiating characteristics are vomiting and diarrhea in a quarter of infected patients, which are rare in sea-
sonal influenza. On June 11, 2009, the World Health Organization declared the first pandemic of the 21st
century, caused by S-OIV A (H1N1). Vaccination is the only way to dampen this pandemic. Many ques-
tions await answers, including the clinical impact of the pandemic, optimal doses of vaccine, and the fu-
ture destiny of the virus. A breakthrough in vaccinology against influenza is needed to address the recurring
influenza pandemic. [J Formos Med Assoc 2009;108(7):526–532]
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presenting symptoms were fever (94%), cough
(92%), and sore throat (66%); 25% of patients
had diarrhea, and 25% had vomiting. Of the 399
patients for whom hospitalization status was
known, 36 (9%) required hospitalization.3 Of 22
hospitalized patients with available data, 12 had
underlying characteristics that conferred an in-
creased risk of severe seasonal influenza, and 11
had radiologically confirmed pneumonia. These
included one (in each group) with pneumome-
diastinum, necrotizing pneumonia, and empyema
that was surgically drained (no microbiological
growth was detected in the fluid). Eight patients
required admission to an intensive care unit, and
four had respiratory failure that required mechan-
ical ventilation. A 22-month-old child with neona-
tal myasthenia gravis and a 33-year-old pregnant
woman have died.3
Therefore, most confirmed cases of novel 
S-OIV A (H1N1) infection have been character-
ized by self-limited, uncomplicated febrile respi-
ratory illness and symptoms similar to those of
seasonal influenza (a cough, a sore throat, rhinor-
rhea, headache, and myalgia). Approximately 38%
of cases have also developed vomiting or diarrhea,
neither of which is typical of seasonal influenza.
Some patients have developed severe illness and
required hospitalized, and two patients have died.
The observation that 60% of patients were ≤ 18
years old suggests that children and young adults
are more susceptible than older persons, or that
because of differences in social networks, trans-
mission to older persons has been delayed. It is
also possible that elderly persons may have had
some level of cross-protection from preexisting
antibodies against other influenza A (H1N1)
viruses—this requires further confirmation.
Is There Any Cross-protection of
Seasonal Influenza Vaccine Against 
the Novel S-OIV A (H1N1)?
The United States Centers for Disease Control
(CDC) has assessed the level of cross-reactive an-
tibody to the novel influenza A (H1N1) virus in
cohorts of children and adults before and after
vaccination with the 2005–2006, 2006–2007,
2007–2008, or 2008–2009 seasonal influenza vac-
cines.4 In children, before vaccination, there were
no cross-reactive antibodies to S-OIV A (H1N1).
Among adults, before vaccination, cross-reactive
antibodies were detected in 6–9% of those aged
18–64 years, and in 33% of those aged > 60
years. Previous vaccination of children with any of
the four seasonal trivalent, inactivated influenza
vaccines (TIVs), or with live attenuated influenza
vaccine, did not elicit a cross-reactive antibody
response to S-OIV A (H1N1).4 In adults aged
18–64 years, vaccination with seasonal TIV re-
sulted in a twofold increase in cross-reactive anti-
body response to S-OIV A (H1N1), compared with
a 12- to 19-fold increase in response to the sea-
sonal H1N1 strain. No increase in cross-reactive
antibody response to the S-OIV A (H1N1) was
observed among adults aged > 60 years.4 These
data suggested that receipt of recent (2005–2009)
seasonal influenza vaccines did not elicit a pro-
tective antibody response to the novel influenza
A (H1N1) virus. In addition, the researchers 
suggested that about one third of those aged 
> 60 years may have had preexisting cross-
reactive antibodies—this may explain why only
5% of S-OIVA (H1N1) patients were ≥ 51 years.3
Case–fatality Rate (CFR) and
Reproduction Number (R0) of 
the Novel H1N1 Influenza
By analyzing the outbreak in Mexico, early data
on international spread, and viral genetic diver-
sity, Fraser et al made an early assessment of trans-
missibility and severity.5 Their estimates suggested
that 23,000 (range, 6000–32,000) of individuals
were infected in Mexico by late April, which gave
an estimated CFR of 0.4% (range, 0.3–1.5%),
based on confirmed and suspect deaths reported
by that time. In a community outbreak in the
small community of La Gloria, Veracruz, no deaths
were attributed to infection, which gave an upper
95% bound CFR of 0.6%. Thus, while substantial
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uncertainty remains, clinical severity appears less
than that seen in 1918 but comparable with that
in 1957.
Clinical attack rate in children aged < 15 years
in La Gloria was 61%, which was more than twice
that in adults aged ≥ 15 years (29%). R0 is defined
as the average number of secondary cases gener-
ated by a primary case. Three different epidemio-
logical analyses estimated R0 to be 1.4–1.6, while
a genetic analysis gave a central estimate of 1.2.
This range of values was consistent with 14 to 73
generations of human-to-human transmission
that occurred in Mexico by late April. Transmissi-
bility was therefore substantially higher than for
seasonal influenza, and comparable with lower
estimates of R0 obtained from previous influenza
pandemics.
Risk Factors for Severe Cases or
Mortality
To date, there is insufficient information about
the clinical complications of S-OIV A (H1N1) 
infection. Deaths have been caused by previous
variants of swine influenza viruses and the novel
H1N1 virus. While data are being collected on the
spectrum of illnesses and complication risk asso-
ciated with infection, clinicians should expect that
both this and seasonal influenza infections will
share the same age and risk factors.
Groups at higher risk of seasonal influenza
complications include: children aged < 5 years;
persons aged ≥ 65 years; children and adolescents
aged < 18 years who are receiving long-term as-
pirin therapy, and who might be at risk for Reye’s
syndrome after influenza; pregnant women; adults
and children who have chronic pulmonary, cardio-
vascular, hepatic, hematological, neurological, neu-
romuscular, or metabolic disorders; adults and
children with immunosuppression caused by med-
ication or human immunodeficiency virus; and
residents of nursing homes and other chronic-care
facilities.
The risk factors for complications of the pres-
ent S-OIV A (H1N1) infection may be similar 
to those of seasonal influenza. However, the
1918 epidemic and the early reports of the pres-
ent S-OIV A (H1N1) outbreak have shown that
younger rather than older people are more sus-
ceptible, and that infected patients of any age
should be observed carefully for the occurrence
of complications.
Transmission: Pandemic Threat and
Infection Control
Pending clarification of transmission patterns for
the S-OIV A (H1N1), the CDC recommends that
personnel providing direct care for patients pre-
senting with febrile respiratory illness (fever 
> 37.8°C, plus one or more of the following: rhi-
norrhea or nasal congestion, sore throat, cough),
in a community in which S-OIV A (H1N1) infec-
tion has been reported, should wear a disposable
N95 respirator, a gown, gloves, and goggles when
entering the patient’s room. The patient should
also wear a surgical mask and be placed in a pri-
vate room, preferably an airborne infection iso-
lation room. These are interim recommendations
and subject to change at any time. Healthcare
personnel entering the room of a patient in iso-
lation should be limited to those performing di-
rect patient care. It is vital to promote good hand
washing and respiratory/cough etiquette for the
prevention of all respiratory infections in the
healthcare setting.
Antiviral Therapy and Post-exposure
Antiviral Chemoprophylaxis
Either oseltamivir or zanamivir is recommended
for treatment of S-OIV A (H1N1) infection, in-
cluding all hospitalized patients with confirmed,
probable, or suspected novel infection, and symp-
tomatic patients who are at higher risk of seasonal
influenza complications. Post-exposure antiviral
chemoprophylaxis with oseltamivir or zanamivir
should be considered for the following: close con-
tacts of cases (confirmed, probable or suspected)
L.Y. Chang, et al
528 J Formos Med Assoc | 2009 • Vol 108 • No 7
and healthcare personnel; public health workers;
or those who have had recognized, unprotected,
close-contact exposure to an infected person (con-
firmed, probable or suspected) during that person’s
infectious period.
Characteristics of Novel S-OIV A (H1N1)
in Humans
Where did the swine influenza virus 
come from?
Influenza A virus can infect various host species,
including birds, humans, and swine. Influenza 
A H1N1 virus was first isolated from swine in
19306 and from humans in 1933.7 Swine influ-
enza A viruses are antigenically very similar to the
1918 human influenza A virus, and they may all
have originated from a common ancestor.8,9 From
1930 to the late 1990s, swine influenza A viruses
were called “classical swine influenza” and they
have remained relatively stable antigenically.10,11
In around 1998, the classical swine influenza
virus resorted with human influenza A H3N2 virus
and a North American Lineage avian influenza
virus (unknown subtype), which resulted in the
emergence of a triple resorted H3N2 swine virus.
This resorted virus has been circulating in the swine
population throughout North America.12–14 Also
in around 1998, the triple resorted H3N2 virus
resorted again with the classical swine influenza
virus. This generated two new subtypes of swine
influenza A virus, the H1N1 and the H1N2
viruses,11 which have been circulating in the
Asian swine population. Although human and
swine H1N1 viruses are all of avian origin, they
have evolved in different host species. Antigenic
drift has occurred amongst different lineages of
H1N1 viruses; therefore, cross-protection anti-
bodies against avian, swine, and human H1N1
viruses are not expected to exist. Indeed, a recent
study has demonstrated that ferret post-infection
antisera raised against the currently circulating,
seasonal human H1N1 viruses did not react with
the novel S-OIV, according to a hemagglutination
inhibition assay.15
The newly emerged S-OIV A (H1N1) contains
a combination of gene segments that have not
been previously identified in swine or human in-
fluenza viruses. The PB2 and PA genes originated
from an avian virus that was introduced into swine
viruses around 1998. PB1 originated from the
human H3N2 virus, which acquired the gene
from an avian virus in 1968. HA, NP, and NS genes
came from classical swine virus and these three
genes are closely related to the 1918 human in-
fluenza A virus. The other two genes, NA and M,
were from the Eurasian swine virus and were in-
troduced to swine viruses in 1979.16 The Figure
depicts the origins of each gene segment of 
S-OIV A (H1N1).
NA and M are the targets of two classes of
clinically used antivirals, oseltamivir (Tamiflu)/
zanamivir (Relenza) and amantadine/rimantadine.
Eurasian swine viruses are oseltamivir-sensitive
and amantadine-resistant. The novel S-OIV A
(H1N1) also has inherited sensitivity to oseltamivir
and resistance to amantadine.16
Virulence factors of S-OIV A (H1N1)
The mortality rate for infection with S-OIV 
A (H1N1) appears not to be particularly high.
However, virulence may change as the number of
adaptive gene mutations increases, and the virus
may have more opportunities to replicate in the
new host species. Like other influenza A viruses,
swine influenza virus enters host cells by binding
to receptors that contain sialic acid. Swine are
known to contain two types of receptors, 2,6-
linked sialic acids that appear abundantly in the
human respiratory tract, and 2,3-linked sialic
acids that tend to be found in avian cells. The
binding affinity of S-OIV A (H1N1) to different
sialic acids is unclear. However, since the S-OIV 
A (H1N1) has been transmitted from human to
human, this virus is expected to bind to human
receptors. However, adaptive mutations may occur
that promote the binding of S-OIV A (H1N1) to
2,6-linked sialic acids, if more humans become
infected in the near future.
Adaptive mutations may occur in any other
gene segments apart from the receptor binding
Novel H1N1 influenza pandemic
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site, and alter viral pathogenesis and virulence.
Currently, predicting which adaptive mutations
will increase or reduce the virulence of S-OIV A
(H1N1) is difficult. However, the following genetic
features may be of interest.
PB2 is a viral ribonucleoprotein subunit that
is responsible for viral replication in cells infected
with influenza virus, and is considered to be a
genetic factor that is associated with host restric-
tion. Almost all of the human influenza A viruses
have lysine (K) at position 627 in the PB2 pro-
tein, and most of the avian viruses have glutamic
acid (E) at this position.17 The E to K mutation in
an avian virus has been shown to increase its vir-
ulence in mammalian experimental systems.18
The PB2 gene segment of S-OIV A (H1N1) has
resorted from an avian influenza A virus of an
unknown subtype and has retained E at position
627. H7N7 avian influenza viruses have infected
humans previously, and one human isolate from
a fatal case has been found to have the E to K
mutation.19 Therefore, monitoring changes in the
amino acid sequence at position 627 of S-OIV 
A (H1N1) in humans is important for predicting
a change in virulence.
PB1-F2 is translated from another reading
frame of the PB1 gene segment because of an al-
ternative translation initiation, and has also been
reported to increase the pathogenicity of the 1918
virus and the highly pathogenic H5N1 virus.18,20
The PB1 gene of the novel S-OIV A (H1N1) has
been found to have truncated forms of PB1-F2
because of the presence of a stop codon at posi-
tion 12. Hence, a point mutation at position 12
may lead to production of a full-length PB1-F2
in the novel S-OIV to increase viral pathogenicity
in humans. However, the mutation may not be
favored in human hosts because human viruses
have tended not to express PB1-F2 as they have
evolved in humans.21
Another well-known virulence factor for the
influenza virus is the NS1 protein. NS1 protein
suppresses the antiviral mechanism in host cells
upon viral infection.22 The C-terminal domain of
the NS1 protein contains the ESEV signal in many
avian influenza A viruses; this signal interacts with
cellular modulators that contain the PDZ domain.
This interaction may increase viral pathogenicity.
Although the NS gene segment of S-OIV A (H1N1)
originated from an avian virus, it is truncated by
L.Y. Chang, et al
530 J Formos Med Assoc | 2009 • Vol 108 • No 7
2009/A/H1N1
NA, M NA, M










Figure. The origin of each gene segment of swine-origin influenza virus A (H1N1). NA and M were derived from the
Eurasian swine virus that originated from the Eurasian avian influenza A virus. The remaining genes were derived from
the triple resorted swine virus that originated from different lineages of avian viruses.
a stop codon at position 220. Hence, NS1 pro-
tein in S-OIV does not have the PDZ ligand do-
main. It is difficult to predict whether a further
mutation in humans will change the sequence at
position 220 and thereby alter the virulence of 
S-OIV A (H1N1).
How Did S-OIV A (H1N1) Overcome Host
Restriction and Pass from Swine to
Humans?
The crossing of host species by the novel S-OIV A
(H1N1) is very important and interesting. Given
the known virulence factors discussed above, the
causes of human infection and its spread among
humans remain unknown. Clearly, other previ-
ously unrecognized molecular determinants are
responsible for the ability of S-OIV A (H1N1) to
replicate and be transmitted in humans. The so-
called species-specific signatures of avian and
human influenza A viruses have been reported.23
We examined the amino acid sequences of S-OIV
A (H1N1) at those species-specific positions and
found that most of the sequences were avian-like
signatures. However, some of them had changed
from avian- to human-like signatures. For exam-
ple, at position 271 of the PB2 gene, the avian-
like signature is T (threonine); whereas the
human-like signature is A (alanine). Most swine
viruses contain T at this position, whereas S-OIV
in humans has A at position 271 of PB2. More
studies should be conducted to identify the un-
recognized molecular markers and thus help to
determine the mechanism by which an animal
influenza A virus crossed the species barrier to
infect humans. Additionally, these molecular de-
terminants will be used to predict viral virulence
and pathogenicity for diagnosis.
Combating the Pandemic: Vaccines
As the S-OIV A (H1N1) infection has become a
pandemic, the most critical question is how to con-
tain it. From the experience so far, it is impossible
to prevent the virus from spreading further be-
cause the first wave of the epidemic hit many 
developed countries and containment has been a
failure. Although this virus remains sensitive to
oseltamivir, the medication is for treatment and
short-term prophylaxis rather than epidemic con-
trol. The only way to control this pandemic is
through large-scale immunization. The production
of vaccines against S-OIV A (H1N1) is feasible;
however, several questions remain unanswered.
First, how many doses are needed to induce ef-
fective protection? For seasonal influenza vaccine,
one dose is sufficient for those aged > 8 years. For
pandemic vaccines such as H5N1, two doses are
needed.24 Second, what is the optimal antigen
content in the vaccine? Seasonal influenza vaccine
contains 15 μg per strain and 45 μg in total.
Without adjuvant, even at 90 μg, H5N1 vaccine
is not sufficiently immunogenic. It is not known
whether adjuvant is needed, or the optimal
amount of antigen in the vaccine. Finally, there is
a historic precedent of rushed production of in-
fluenza vaccine to contain swine influenza (as
demonstrated in 1976). Unfortunately, an increase
in the incidence of Guillain-Barré syndrome was
demonstrated in the same year and vaccination
had to be stopped.25 The mechanism remains
uncertain, although the antiganglioside antibody
was raised as a possible explanation.26 How to
prevent this from being repeated in 2009 is an
area of concern.
Conclusion
Forty-one years after the last influenza pandemic,
we have witnessed the first pandemic caused by a
novel S-OIV A (H1N1) in the 21st century. With
our knowledge and experience about influenza
viruses, we should be able to cope with this pan-
demic with the least possible morbidity and
mortality. Vaccination is the only effective way to
stop this pandemic and will be available in late
2009. More understanding of influenza viruses
and continuous development of broad-spectrum
influenza vaccines are of critical importance.
Novel H1N1 influenza pandemic
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